CompletedNCT02352051
Atomoxetine or Methylphenidate for Executive Function in Children
About this title
Read the official source — NCT02352051Medication studyAges 7–12ADHD
Understand this study
Who was this study for?
Listed age limits: 7 years to 12 years.
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateFebruary 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 43
- Sponsor
- TC Erciyes University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Not clearly listed
- Age range
- From 7 Years to 12 Years
- Official registry ID
- NCT02352051
- Official title
Show the full official title
Effects of Atomoxetine and Oros-mph on Executive Functions in Patients With Combined Type Attention Deficit Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Locations not listed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is TC Erciyes University, a university.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine and methylphenidate.
Who was this study for?
Listed age limits: 7 years to 12 years.
